Combined-modality therapy for gastric cancer

Area of Science:

• Oncology
• Surgical Oncology
• Radiation Oncology

Background:

• Gastric cancer often presents with a poor prognosis, frequently diagnosed at advanced stages.
• Curative treatments are limited, and even after surgical resection, long-term survival is low with frequent locoregional failures.

Purpose of the Study:

• To evaluate the efficacy of postoperative adjuvant chemoradiotherapy in improving outcomes for gastric cancer patients.
• To establish a new standard of care for patients undergoing resection for gastric carcinoma.

Main Methods:

• Review of earlier studies demonstrating survival benefits of chemoradiotherapy for unresectable gastric cancer.
• Analysis of the Intergroup 0116 trial comparing surgery alone versus surgery plus postoperative chemotherapy and chemoradiotherapy.

Main Results:

• The Intergroup 0116 trial demonstrated superior overall and disease-free survival rates in patients receiving combined-modality postoperative therapy.
• These findings established combined-modality postoperative therapy as a new standard of care.

Conclusions:

• Postoperative chemoradiotherapy offers notable benefits for gastric cancer patients following resection.
• Future research focuses on preoperative chemoradiotherapy, novel radioenhancers, and molecularly selected therapies to further advance gastric cancer treatment.